Current read
Clinical traction from 34 study records, 81 active source records, 4 rapid briefs, and 7 timeline events. Evidence maturity is 87/100, human translation signal is 76/100, and frontier activity is extreme (100/100). Frontier activity means research movement, not settled human proof.
This lane has stronger human/clinical support, but still needs bounded claims.
Commercial bias penalty: 69/100. Confidence: 84/100. Frontier activity means research movement, not settled human proof.
Why this row matters
Insulin, GLP-1, energy balance, mTOR/AMPK pathways, metabolic flexibility, and body-composition effects. The map tracks whether this lane is moving from biological plausibility toward outcomes people can responsibly discuss.
Current human translation
Human translation is 100/100 based on human-facing studies, clinical/regulatory sources, claims, and published coverage.
Main approaches being tracked
GLP-1 medicines, protein and resistance training, glucose and lipid risk monitoring.
What would move this row up?
Current bottleneck
Replication, durability, and sharper endpoint evidence.
Milestones that would move this row up
Row movement
Mini timeline
Newest graph events across studies, sources, briefs, claims, and timeline records
Open evidence gaps
These gaps are matched from the evidence-gap ledger where possible, with row-level placeholders used when the graph is not yet enriched.
Long-term healthy-aging functional outcomes beyond weight loss.
Long-term healthy-aging functional outcomes beyond weight loss.
Lean-mass preservation and post-discontinuation maintenance evidence.
Lean-mass preservation and post-discontinuation maintenance evidence.
Evidence that would change the map
- Raise evidence maturity from 87/100 with better controlled studies or stronger replication.
- Raise human translation from 100/100 with outcomes that matter in people, not only biomarkers or mechanisms.
- Preserve safety discipline with clearer limitations, contraindications, and overclaim boundaries as activity grows.
What not to overclaim
- Do not call weight loss age reversal.
- Do not generalize outcome benefits beyond studied cardiometabolic populations.
Research map
Related studies
Study records matched through topic tags, intervention IDs, source IDs, related content, or row-specific tags.
No structured study records are attached to this row yet.
Useful source library entries
Related briefs
Medicare Launched a $50 GLP-1 Access Bridge
CMS launched a temporary GLP-1 Bridge for eligible Part D beneficiaries, but the program is limited, temporary, and not universal Medicare obesity-drug coverage.
Why now
A major cost barrier around obesity pharmacotherapy shifted for a subset of Medicare beneficiaries.
- Overclaim risk
- high
- Primary source
- Official
- Published
- Jul 5, 2026
GLP-1 Drugs Linked to Higher Smell and Taste Disturbance Risk
A large EHR cohort study found GLP-1 RA users with type 2 diabetes had higher documented smell and taste disturbance risk, though absolute rates were low.
Why now
GLP-1 safety signals are socially viral and need careful absolute-risk framing.
- Overclaim risk
- medium-high
- Primary source
- Primary
- Published
- Jun 30, 2026
Generic Tirzepatide Challengers Enter FDA Review
Sandoz and Hybio said FDA accepted generic tirzepatide applications, opening a new phase in the long access fight around Mounjaro and Zepbound.
Why now
GLP-1 attention is shifting from efficacy to access, patents, pricing, supply, and generic strategy.
- Overclaim risk
- medium-high
- Primary source
- Trade news
- Published
- Jun 30, 2026
The Compounded GLP-1 Boom Is Becoming a Patient-Safety and Trust Crisis
The weight-loss drug boom created a shadow market of compounded GLP-1s, fake labels, telehealth claims, dosing confusion, and patients who may not know what they are actually getting.
Why now
Regulatory warnings and investigations are converging on the same problem: patients cannot always tell what product they are receiving.
- Overclaim risk
- medium-high
- Primary source
- Trade news
- Published
- Jun 24, 2026
Latest graph movement
2021 / trial
STEP 1
Semaglutide obesity trial in adults with overweight or obesity without diabetes.
2022 / trial
SURMOUNT-1
Tirzepatide obesity trial broadened the category beyond single-agonist therapy.
2023 / trial
SELECT
Cardiovascular outcomes data in adults with overweight or obesity and established cardiovascular disease without diabetes.
2024 / trial
FLOW
Kidney outcomes data in people with type 2 diabetes and chronic kidney disease.
2024 / regulatory
Wegovy cardiovascular-risk approval
FDA expanded the label for a specific population with cardiovascular disease and overweight or obesity.
2024 / regulatory
SURMOUNT-OSA and Zepbound approval
Tirzepatide data and FDA approval for moderate-to-severe obstructive sleep apnea in adults with obesity.
2025 / regulatory
ESSENCE and Wegovy MASH approval
Semaglutide evidence and FDA approval for noncirrhotic MASH with moderate-to-advanced fibrosis.
Related published coverage
Published coverage contributes to coverage depth, not evidence maturity by itself.
Seed Oils: Toxic Sludge or Internet Scapegoat?
Seed oils are blamed for inflammation, obesity, heart disease, and metabolic collapse. The stronger signal is not that linoleic-acid-rich oils are toxic. It is that they often travel inside ultra-processed food patterns.
VV Signal Score
55
Early or context-dependent
- Sources
- 7
- Studies
- 6
- Claims
- 10
Calories Are the Accounting System, Not the Whole Metabolic Story
Weight loss requires an energy deficit, but calories alone do not explain appetite, metabolism, food environment, hormones, lean mass, sleep, medications, or long-term maintenance.
VV Signal Score
83
Strong signal
- Sources
- 13
- Studies
- 10
- Claims
- 8
The Carnivore Diet Is a Real Experiment, Not a Settled Science
Carnivore eating may change weight, symptoms, and biomarkers for some people. The direct evidence is still too thin to establish broad benefit or long-term safety.
VV Signal Score
42
Mixed signal
- Sources
- 12
- Studies
- 12
- Claims
- 9
CGMs for Non-Diabetics: Metabolic Radar or Anxiety Subscription?
Continuous glucose monitors are moving from diabetes care into consumer metabolic self-tracking. That can help some people understand meals, sleep, stress, exercise, and risk. It can also turn normal physiology into false precision, food fear, and subscription anxiety.
VV Signal Score
58
Early or context-dependent
- Sources
- 7
- Studies
- 6
- Claims
- 4
Sweeteners: Sugar Escape Hatch or Metabolic Shell Game?
Sweetener discourse is a mess because the category is too broad. Allulose, erythritol, aspartame, stevia, monk fruit, and sugar alcohols differ by calories, metabolism, gut tolerance, regulatory treatment, cardiovascular questions, cancer controversy, and what they replace in the diet.
VV Signal Score
62
Early or context-dependent
- Sources
- 8
- Studies
- 8
- Claims
- 5
Ultra-Processed Foods and Protein Everything: Protein Halo or Processing Penalty?
Ultra-processed food debates are usually too crude. The useful question is which mechanisms drive harm: energy density, eating rate, texture, fiber, protein dilution, palatability, additives, food matrix, or processing itself. Protein can be protective, but protein-branded products can still be ultra-processed.
VV Signal Score
73
Promising signal
- Sources
- 8
- Studies
- 8
- Claims
- 5
Claim ledger
Related claims
Claim ledger records matched by topic, intervention, study, or source links.
weight loss: Sustained fat loss requires net energy deficit, but the
Sustained fat loss requires net energy deficit, but the appetite, expenditure, adaptation, and maintenance systems that shape that deficit are biologically regulated.
weight loss: Calories describe the accounting of tissue-energy change, but they
Calories describe the accounting of tissue-energy change, but they do not explain all biological friction around appetite, expenditure, adaptation, food environment, hormones, sleep, lean mass, and maintenance.
ultra processed food: Ultra-processed diets can increase spontaneous calorie intake and weight
Ultra-processed diets can increase spontaneous calorie intake and weight gain under controlled inpatient conditions, even when presented diets are broadly matched for macronutrients, sugar, sodium, and fiber.
weight loss: Large weight loss can reduce resting energy expenditure beyond
Large weight loss can reduce resting energy expenditure beyond what body-size change alone predicts, illustrating that calories-out is adaptive rather than fixed.
low carb: Insulin and carbohydrate quality matter, but controlled feeding evidence
Insulin and carbohydrate quality matter, but controlled feeding evidence does not support a simple insulin-only explanation of obesity or fat loss.
thyroid: Hypothyroidism can contribute to weight gain by lowering calorie
Hypothyroidism can contribute to weight gain by lowering calorie expenditure, but typical thyroid-related weight change is often bounded and should not be used as a universal explanation for weight gain.